Amgen Positions Itself in the Obesity Medication Market! The Stock Shows Strong Rebound After the Suspension of Tariffs

Despite stable demand, the healthcare sector, like the rest of the market, has experienced a setback. However, this pharmaceutical giant could significantly increase its profits in the coming years. Amgen (i) has been affected by the general market downturn, but its business remains unscathed. Revenues from obesity medications are poised for a boom, which could make the stock an interesting investment. Amgen produces a lot domestically and could avoid potential tariffs Another concern for Amgen investors is the fact that Trump has threatened...